News | July 22, 2023
Merck receives positive European Union CHMP opinion for Gefapixant
The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union
The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
This four-day course is designed for professionals in the pharmaceutical, nutraceutical, and related industries
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
The company is already marketing the 4 mg and 10 mg strengths
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
Dignitaries and delegates commend India’s leadership in Global South during G20 India Presidency
Convergent action on AMR identified as an important area of intervention
Subscribe To Our Newsletter & Stay Updated
